138 related articles for article (PubMed ID: 28646078)
1. Stereospecific Metabolism of
Barnette DA; Johnson BP; Pouncey DL; Nshimiyimana R; Desrochers LP; Goodwin TE; Miller GP
Drug Metab Dispos; 2017 Sep; 45(9):1000-1007. PubMed ID: 28646078
[TBL] [Abstract][Full Text] [Related]
2. Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases.
Malátková P; Sokolová S; Chocholoušová Havlíková L; Wsól V
Biochem Pharmacol; 2016 Jun; 109():83-90. PubMed ID: 27055738
[TBL] [Abstract][Full Text] [Related]
3. Effect of experimental kidney disease on the functional expression of hepatic reductases.
Alshogran OY; Naud J; Ocque AJ; Leblond FA; Pichette V; Nolin TD
Drug Metab Dispos; 2015 Jan; 43(1):100-6. PubMed ID: 25332430
[TBL] [Abstract][Full Text] [Related]
4. High-affinity stereoselective reduction of the enantiomers of ketotifen and of ketonic nortriptyline metabolites by aldo-keto reductases from human liver.
Breyer-Pfaff U; Nill K
Biochem Pharmacol; 2000 Feb; 59(3):249-60. PubMed ID: 10609553
[TBL] [Abstract][Full Text] [Related]
5. Stereoselective acetonyl side chain reduction of warfarin and analogs. Partial characterization of two cytosolic carbonyl reductases.
Hermans JJ; Thijssen HH
Drug Metab Dispos; 1992; 20(2):268-74. PubMed ID: 1352220
[TBL] [Abstract][Full Text] [Related]
6. Warfarin metabolites: stereochemical aspects of protein binding and displacement by phenylbutazone.
Chan E; McLachlan AJ; Rowland M
Chirality; 1993; 5(8):610-5. PubMed ID: 8305289
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Novel Reductive Elimination Pathway for 10-Hydroxywarfarin.
Pouncey DL; Barnette DA; Sinnott RW; Phillips SJ; Flynn NR; Hendrickson HP; Swamidass SJ; Miller GP
Front Pharmacol; 2021; 12():805133. PubMed ID: 35095511
[TBL] [Abstract][Full Text] [Related]
8. Enantioselectivity of carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone by tissue fractions from human and rat and by enzymes isolated from human liver.
Breyer-Pfaff U; Martin HJ; Ernst M; Maser E
Drug Metab Dispos; 2004 Sep; 32(9):915-22. PubMed ID: 15319331
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins.
Kim SY; Kang JY; Hartman JH; Park SH; Jones DR; Yun CH; Boysen G; Miller GP
Drug Metab Lett; 2012 Sep; 6(3):157-64. PubMed ID: 23331088
[TBL] [Abstract][Full Text] [Related]
10. Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man.
Wsol V; Szotakova B; Martin HJ; Maser E
Toxicology; 2007 Sep; 238(2-3):111-8. PubMed ID: 17618725
[TBL] [Abstract][Full Text] [Related]
11. Novel multi-mode ultra performance liquid chromatography-tandem mass spectrometry assay for profiling enantiomeric hydroxywarfarins and warfarin in human plasma.
Jones DR; Boysen G; Miller GP
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 May; 879(15-16):1056-62. PubMed ID: 21470921
[TBL] [Abstract][Full Text] [Related]
12. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases.
Rosemond MJ; St John-Williams L; Yamaguchi T; Fujishita T; Walsh JS
Chem Biol Interact; 2004 Mar; 147(2):129-39. PubMed ID: 15013815
[TBL] [Abstract][Full Text] [Related]
13. Properties and stereoselectivity of carbonyl reductases involved in the ketone reduction of warfarin and analogues.
Hermans JJ; Thijssen HH
Adv Exp Med Biol; 1993; 328():351-60. PubMed ID: 8493912
[No Abstract] [Full Text] [Related]
14. Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe.
Zhang Z; Fasco MJ; Huang Z; Guengerich FP; Kaminsky LS
Drug Metab Dispos; 1995 Dec; 23(12):1339-46. PubMed ID: 8689941
[TBL] [Abstract][Full Text] [Related]
15. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
[TBL] [Abstract][Full Text] [Related]
16. Warfarin: stereochemical aspects of its metabolism in vivo in the rat.
Pohl LR; Bales R; Trager WF
Res Commun Chem Pathol Pharmacol; 1976 Oct; 15(2):233-56. PubMed ID: 981784
[TBL] [Abstract][Full Text] [Related]
17. Warfarin and UDP-glucuronosyltransferases: writing a new chapter of metabolism.
Jones DR; Moran JH; Miller GP
Drug Metab Rev; 2010 Feb; 42(1):55-61. PubMed ID: 19788348
[TBL] [Abstract][Full Text] [Related]
18. Reductive metabolism of tiaprofenic acid by the human liver and recombinant carbonyl reducing enzymes.
Malátková P; Skarka A; Musilová K; Wsól V
Chem Biol Interact; 2017 Oct; 276():121-126. PubMed ID: 28322780
[TBL] [Abstract][Full Text] [Related]
19. Combination index of the concentration and in vivo antagonism activity of racemic warfarin and its metabolites to assess individual drug responses.
Kobayashi S; Ishii K; Yamada Y; Ryu E; Hashizume J; Nose S; Hara T; Nakashima M; Ohyama K
J Thromb Thrombolysis; 2019 Apr; 47(3):467-472. PubMed ID: 30465164
[TBL] [Abstract][Full Text] [Related]
20. The disposition of the enantiomers of warfarin following chronic administration to rats: relationship to anticoagulant response.
Pratt SK; Winn MJ; Park BK
J Pharm Pharmacol; 1989 Nov; 41(11):743-6. PubMed ID: 2576040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
